| Keywords: |
adult; cancer chemotherapy; child; treatment outcome; aged; clinical trial; review; doxorubicin; drug efficacy; united states; comparative study; cytarabine; prospective studies; blood toxicity; europe; acute leukemia; drug mechanism; randomized controlled trials; cardiotoxicity; daunorubicin; idarubicin; intravenous drug administration; recombinant interleukin 2; oral drug administration; leukemia, myelocytic, acute; clinical trials, phase ii; clinical trials, phase i; leukemia, lymphocytic, acute; human
|
